Differential human multiple myeloma cell line responsiveness to interferon-α: Analysis of transcription factor activation and interleukin 6 receptor expression

Journal of Clinical Investigation

Volumn 99, Issue 3, 1997, Pages 447-456

  Jelinek, Diane F ^a,b   Aagaard Tillery, Kjersti M ^a   Arendt, Bonnie K ^a   Arora, Taruna ^a   Tschumper, Renee C ^a   Westendorf, Jennifer J ^a  

^a MAYO CLINIC   (United States)

^b MAYO GRADUATE SCHOOL   (United States)

Author keywords

Autocrine IL 6; Cell cycle; Growth factor; IFN ; Myeloma

Indexed keywords

GAMMA INTERFERON; IMMUNOGLOBULIN G1; INTERLEUKIN 6 RECEPTOR; MONOCLONAL ANTIBODY; POLYCLONAL ANTIBODY; RECOMBINANT ALPHA2B INTERFERON; RECOMBINANT INTERLEUKIN 6; STAT1 PROTEIN; STAT2 PROTEIN; STAT3 PROTEIN; TRANSCRIPTION FACTOR;

ARTICLE; CANCER CELL CULTURE; CANCER GROWTH; CONTROLLED STUDY; DRUG MECHANISM; GENE EXPRESSION; HUMAN; HUMAN CELL; MULTIPLE MYELOMA; MYELOMA CELL; PRIORITY JOURNAL; RECEPTOR BINDING; RECEPTOR DOWN REGULATION; SIGNAL TRANSDUCTION;

EID: 0030881360     PISSN: 00219738     EISSN: None     Source Type: Journal    
DOI: 10.1172/JCI119179     Document Type: Article

References (49)

1. Pestka, S., J. Langer, K.C. Zoon, and C. Samuel. 1987. Interferons and their actions. Annu. Rev. Biochem. 56:727-777.
2. Gutterman, J.U. 1994. Cytokine therapeutics: lessons from interferon α. Proc. Natl. Acad. Sci. USA. 91:1198-1205.
3. Gresser, I. 1991. Antitumour effects of interferons: past, present and future. Br. J. Haematol. 79:1-5.
4. Mellstedt, H., A. Ahre, M. Bjorkholm, G. Holm, B. Johansson, and H. Strander. 1979. Interferon therapy in myelomatosis. Lancet. 1:245-247.
5. Oken, M.M. 1994. Standard treatment of multiple myeloma. Mayo Clin. Proc. 69:781-786.
6. Browman, G.P., D. Bergsagel, D. Sicheri, S. O'Reilly, K.S. Wilson, S. Rubin, A. Belch, C. Shustik, R. Barr, I. Walker, et al. 1995. Randomized trial of interferon maintenance in multiple myeloma: a study of the National Cancer Institute of Canada clinical trials group. J. Clin. Oncoi. 13:2354-2360.
7. Ludwig, H., A.M. Cohen, A. Polliack, H. Huber, D. Nachbaur, H.-J. Senn, R. Morant, S. Eckhardt, P. Günczler, H.L. Seewann, et al. 1995. Interferon-alpha for induction and maintenance in multiple myeloma: results of two multicenter randomized trials and summary of other studies. Ann. Oncol. 6: 467-176.
8. Bladé, J., A. López-Guillermo, D. Tassies, E. Montserrat, and C. Rozman. 1991. Development of aggressive plasma cell leukaemia under interferon-alpha therapy. Br. J. Haematol. 79:523-525.
9. Sawamura, M., K. Murayama, G. Ui, T. Matsushima, J. Tamura, H. Murakami, T. Naruse, and J. Tsuchiya. 1992. Plasma cell leukaemia with alpha-interferon therapy in myeloma. Br. J. Haematol. 82:631.
10. Brenning, G. 1985. The in vitro effect of leucocyte α-interferon on human myeloma cells in a semisolid agar culture system. Scand. J. Haematol. 35: 178-185.
11. Brenning, G., A. Ahre, and K. Nilsson. 1985. Correlation between in vitro and in vivo sensitivity to human leucocyte interferon in patients with multiple myeloma. Scand. J. Haematol. 35:543-549.
12. Jourdan, M., X.G. Zhang, M. Portier, J.-M. Boiron, R. Bataille, and B. Klein. 1991. IFN-α induces autocrine production of IL-6 in myeloma cell lines. J. lmmunol. 147:4402-4407.
13. 2-microglobulin in the human myeloma cell line U-266 and in an α-interferon resistant U-266 subline. Scand. J. Haematol. 37:280-288.
14. Einhorn, S., J.-O. Fernberg, D. Grandér, and R. Lewensohn. 1988. Interferon exerts a cytotoxic effect on primary human myeloma cells. Eur. J. Cancer Clin. Oncol. 24:1505-1510.
15. Schwabe, M., A.T. Brini, M.C. Bosco, F. Rubboli, M. Egawa, J. Zhao, G.L. Princler, and H. Kung. 1994. Disruption by interferon-α of an autocrine interleukin 6 growth loop in IL-6-dependent U266 myeloma cells by homologous and heterologous downregulation of the IL-6 receptor α and βchains. J. Clin. Invest. 94:2317-2325.
16. Anthes J.C., Z. Zhan, H. Gilchrest, R.W. Egan, M.I. Siegel, and M.M. Billah. 1995. Interferon-α down-regulates the interleukin-6 receptor in a human multiple myeloma cell line, U266. Biochem. J. 309:175-180.
17. Kawano, M., T. Hirano, T. Matsuda, T. Taga, Y. Horii, K. Iwato, B. Tang. O. Tanabe, H. Tanaka, A. Kuramoto, and T. Kishimoto. 1988. Autocrine generation and requirement of BSF-2/1L6 for human multiple myeloma. Nature (Lond.). 332:83-85.
18. Palumbo, A., S. Battaglio, P. Napoli, P. Omedè, A. Fusaro, B. Bruno, M. Boccadoro, and A. Pileri. 1994. Recombinant Interferon-γ inhibits the in vitro proliferation of human myeloma cells. Br. J. Haematol 86:726-732.
19. Portier, M., X.-G. Zhang, E. Caron, Z.-Y. Lu, R. Bataille, and B. Klein. 1993. γ-Interferon in multiple myeloma: inhibition of interleukin-6 (IL-6)-dependent myeloma cell growth and downregulation of IL-6-receptor expression in vitro. Blood. 81:3076-3082.
20. Ihle, J.N. 1995. The Janus protein tyrosine kinase family and its role in cytokine signaling. Adv. Immunol. 60:1-35.
21. Schindler, C., and J.E. Darnell, Jr. 1995. Transcriptional responses to polypeptide ligands: the JAK/STAT pathway. Annu. Rev. Biochem. 64:621-651.
22. Harroch, S., M. Revel, and J. Chebath. 1994. Induction by inturleukin-6 of interferon regulatory factor 1 (IRF-1) gene expression through the palindromic interferon response element pIRE and cell type-dependent control of IRF-1 binding to DNA. EMBO (Eur. Mol. Biol. Organ.) J. 13:1942-1949.
23. Harroch, S., Y. Gothelf, N. Watanabe, M. Revel, and J. Chebath. 1993. Interleukin-6 activates and regulates transcription factors of the interferon regulatory factor family in M1 cells. J. Biol. Chem. 268:9092-9097.
24. Taniguchi, T., H. Harada, and M. Lamphier. 1995. Regulation of the interferon system and cell growth by the IRF transcription factors. J. Cancer Res. Clin. Oncol. 121:516-520.
25. Tanaka, N., M. Ishihara, M. Kitagawa, H. Harada, T. Kimura, T. Matsuyama, M.S. Lamphier. S. Aizawa, T.W. Mak, and T. Taniguchi. 1994. Cellular commitment to oncogene-induced transformation or apoptosis is dependent on the transcription factor IRF-1. Cell. 77:829-839.
26. Minami, M., M. Inoue, S. Wei, K. Takeda, M. Matsumoto, T. Kishimoto, and S. Akira. 1996. STAT3 activation is a critical step in gp130-mediated terminal differentiation and growth arrest of a myeloid cell line. Proc. Natl. Acad. Sci. USA. 93:3963-3966.
27. Yamanaka, Y., K. Nakajima, T. Fukada, M. Hibi, and T. Hirano. 1996. Differentiation and growth arrest signals are generated through the cytoplasmic region of gp130 that is essential for Stat3 activation. EMBO (Ear. Mol. Biol. Organ.) J. 15:1557-1565.
28. Yang, C-H., W. Shi, L. Basu, A. Murti, S.N. Constantinescu, L. Blatt. E. Croze, J.E. Mullersman, and L.M. Pfeffer. 1996. Direct association of STAT3 with the IFNAR-1 chain of the human type I interferon receptor. J. Biol. Chem. 271:8057-8061.
29. WAF1/CIP1 mediated by STAT1. Science (Wash. DC). 272:719-722.
30. Jelinek, D.F., G.J. Ahmann, P.R. Greipp, S.M. Jalal, J.J. Westendorf. J.A. Katzmann, R.A. Kyle, and J.A. Lust. 1993. Coexistence of aneuploid subclones within a myeloma cell line that exhibits clonal immunoglobulin gene rearrangement: clinical implications. Cancer Res. 53:5320-5327.
31. Westendorf, J.J., G.J. Ahmann, P.R. Greipp, T.E. Witzig, R.A. Kyle, J.A. Lust, and D.F. Jelinek. 1996. Establishment and characterization of three myeloma cell lines that demonstrate variable cytokine responses and abilities to produce autocrine interleukin-6. Leukemia. 10:866-876.
32. Wagner, B.J., T.E. Hughes, C.J. Hogan, and B.H. Cochran. 1990. The SIF binding element confers sis/PDGF inducibility onto the c-fos promoter. EMBO (Eur. Mol. Biol. Organ.) J. 9:4477-4484.
33. Ali Imam, A.M., A.M. Ackrill, T.C. Dale, I.M. Kerr, and G.R. Stark. 1990). Transcription factors induced by interferons α and γ. Nucleic Acids Res. 18:6573-6580).
34. Gao, P.-Q., S.H. Sims, D.C. Chang, and A.B. Deisseroth. 1993. Interferon-γ priming effects in the activation and deactivation of ISGF3 in K562 cells. J. Biol. Chem. 268:12380-12387.
35. Sadowski, H.B. K. Shuai, J.E. Darnell, Jr., and M.Z. Gilman. 1993. A common nuclear signal transduction pathway activated by growth factor and cytokine receptors. Science (Wash. DC). 261:1739-1744.
36. Zhang. X., J. Blenis, H.-C. Li, C. Schindler, and S. Chen-Kiang. 1995. Requirement of serine phosphorylation for formation of STAT-promoter complexes. Science (Wash. DC). 267:1990-1994.
37. Williams, B.R.G. 1991. Transcriptional regulation of interferon-stimulated genes. Ear. J. Biochem. 2001:11.
38. Tanaka, N., and T. Taniguchi. 1992. Cytokine gene regulation: regulatory cis-elements and DNA binding factors involved in the interferon system. Adv.Immunol.52:263-281.
39. Williams, B.R.G., and I.M. Kerr. 1980. The 2-5A system in interferon-treated and control cells. Trends, Biochem. Sci. 5:138-140.
40. Heslop, H.E., A.C.M. Bianchi, F.T. Cordingley, M. Truner, W.C.P. De Mel, A.V. Hoffbrand, and M.K. Brenner. 1990. Effects of interferon α on autocrine growth factor loops in B lymphoproliferative disorders. J. Exp. Med. 172: 1729-1734.
41. Westendorf. J.J., G.J. Ahmann, R.J. Armitage, M.K. Spriggs, J.A. Lust. P.R. Greipp. J.A. Katzmann, and D.F. Jelinek. 1994. CD40 expression in malignant plasma cells: role in stimulation of autocrine IL-6 secretion by a human myeloma cell line. J. lmmunol. 152:117-128.
42. Yamada, G., M. Ogawa, K. Akagi, H. Miyamoto, N. Nakano, S. Itoh, J.-I. Miyazaki, S.-I. Nishikawa, K.-I. Yamamura, and T. Taniguchi. 1991. Specific depletion of the B-cell population induced by aberrant expression of human interferon regulatory factor 1 gene in transgenic mice. Proc. Natl. Acad. Sci. USA. 88:532-536.
43. Harada, H., M. Kitagawa, N. Tanaka, H. Yamamoto, K. Harada, M. Ishihara, and T. Taniguchi. 1993. Anti-oncogenic and oncogenic potentials of interferon regulatory factors-1 and -2. Science (Wash. DC). 259:971-974.
44. Friedman, R.L., S.P. Manly, M. McMahon, I.M. Kerr, and G.R. Stark, 1984. Transcriptional and post-transcriptional regulation of interferon-induced gene expression in human cells. Cell. 38:745-755.
45. Larner, A.C., A. Chaudhuri. and J.E. Darnell, Jr. 1986. Transcriptional induction by interferon. J. Biol. Chem. 261:453-459.
46. Harvey, W.H., O.S. Harb, S.T. Kosak, J.C. Sheaffer, L.R. Lowe, and N.A. Heerema. 1994. Interferon-alpha-2b downregulation of oncogenes H-ras. c-raf-2, c-kit, c-myc, c-myb and c-fos in eskol, a hairy cell leukemic line, results in temporal perturbation of signal transduction cascade. Leukemia Res. 18:577-585.
47. H2 lymphocytes express type I and type II IL-1 receptors, but only the type I receptor mediates costimulatory activity. J. lmmunol 151:3500-3510.
48. Sims, J.E., M.A. Gayle, J.L. Slack. M.R. Alderson, TA. Bird, J.D. Giri, F. Colotta, F. Re, A. Mantovani, K. Shanebeck, et al. 1993. lnterleukin 1 signaling occurs extensively via the type I receptor. Proc. Natl. Acad. Sci. USA. 90: 6155-6159.
49. Kishimoto, T., S. Akira, M. Narazaki, and T. Taga. 1995. lnterleukin-6 family of cytokines and gp130. Blood. 86:1243-1254.